Critical Therapeutics, Inc. Announces Issuance Of U.S. Patent Relating To HMGB1 For Methods To Diagnose Arthritis And Lupus
LEXINGTON, Mass.--(BUSINESS WIRE)--July 12, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced the issuance of a U.S. patent for methods of diagnosing and monitoring the severity of several inflammatory conditions, including arthritis and lupus, by measuring the concentration of a key protein present in a patient's bloodstream.